Literature DB >> 8710133

Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up.

Y Nevo1, A Pestronk, A J Kornberg, A M Connolly, W C Yee, I Iqbal, L K Shield.   

Abstract

Chronic inflammatory demyelinating neuropathy (CIDP) is a rare disease in childhood. We reviewed the clinical characteristics, response to therapy, and long-term prognosis in 13 children (1.5 to 16 years of age) diagnosed with CIDP at Washington University Medical Center, St. Louis, and the Royal Children's Hospital, Melbourne, Australia, between 1979 and 1994. The most common presenting symptom (in 11/13 [85%]) was lower extremity weakness associated with difficulty in walking. Preceding events within 1 months of onset, mostly intercurrent infections or vaccinations, occurred in seven children (54%). The disease was monophasic in three children (23%). One relapse occurred in four (30%) and multiple relapses in six (46%). All patients had at least short-term response to steroids. Three children (23%) recovered completely during the first year. Ten children (77%) had residual weakness after an average follow-up of 6 years. There seems to be two populations of children with CIDP. One subgroup, with a favorable prognosis, progressed to peak disability over less than 3 months; these children often have a monophasic course with complete resolution of symptoms and signs and withdrawal from all medications by 1 year after onset. A second subgroup progressed for 3 months or longer; these children all required substantial does of prednisone for prolonged periods and had considerable long-term morbidity with persistent weakness.

Entities:  

Mesh:

Year:  1996        PMID: 8710133     DOI: 10.1212/wnl.47.1.98

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

Review 1.  Chronic inflammatory demyelinative polyneuropathy.

Authors:  Gérard Said
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

Review 2.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  G Comi; L Roveri
Journal:  Ital J Neurol Sci       Date:  1998-10

Review 3.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  IVIG therapy in neurological disorders of childhood.

Authors:  Juan J Archelos; Franz Fazekas
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 5.  Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard Ac Hughes; Man Mohan Mehndiratta; Yusuf A Rajabally
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

Review 6.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

Review 7.  Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.

Authors:  Peter J Dyck; Bruce V Taylor; Jenny L Davies; Michelle L Mauermann; William J Litchy; Christopher J Klein; P James B Dyck
Journal:  Muscle Nerve       Date:  2015-08-13       Impact factor: 3.217

8.  Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.

Authors:  Alberto Spalice; Pasquale Parisi; Laura Papetti; Francesco Nicita; Fabiana Ursitti; Francesca Del Balzo; Enrico Properzi; Alberto Verrotti; Martino Ruggieri; Paola Iannetti
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

9.  Inflammatory demyelinating neuropathies.

Authors:  Glenn Lopate; Alan Pestronk
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.972

10.  Pediatric CIDP: Diagnosis and Management. A Single-Center Experience.

Authors:  Małgorzata Łukawska; Anna Potulska-Chromik; Marta Lipowska; Dorota Hoffman-Zacharska; Beata Olchowik; Magdalena Figlerowicz; Karolina Kanabus; Edyta Rosiak; Anna Kostera-Pruszczyk
Journal:  Front Neurol       Date:  2021-07-02       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.